CYTOKINETICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $88.0M | $18.5M | $7.5M | $94.6M | $70.4M |
| Research and development | $416.0M | $339.4M | $330.1M | $240.8M | $159.9M |
| Operating expenses | $700.3M | $554.7M | $503.7M | $418.8M | $256.7M |
| Operating income | -$612.3M | -$536.2M | -$496.2M | -$324.2M | -$186.3M |
| Interest expense | $45.6M | $37.7M | $28.3M | $19.4M | $16.4M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$785.0M | -$589.5M | -$526.2M | -$389.0M | -$215.3M |
| Balance Sheet | |||||
| Cash and equivalents | $122.5M | $94.9M | $113.0M | $65.6M | $112.7M |
| Current assets | $917.0M | $1.1B | $628.1M | $795.2M | $535.7M |
| Total assets | $1.4B | $1.4B | $824.3M | $1.0B | $841.3M |
| Current liabilities | $202.5M | $179.7M | $102.7M | $84.6M | $71.9M |
| Total liabilities | $2.1B | $1.5B | $1.2B | $1.1B | $597.5M |
| Total debt | $999.0M | — | — | — | — |
| Stockholders' equity | -$659.6M | -$135.4M | -$386.3M | -$107.9M | $243.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$510.0M | -$395.9M | -$414.3M | -$299.5M | -$142.5M |
| Depreciation and amortization | $10.1M | $9.5M | $11.9M | $5.8M | $2.3M |
| Stock-based compensation | $112.3M | $97.8M | $72.1M | $47.9M | $26.8M |
| Capital expenditure | $24.8M | $3.9M | $1.4M | $11.3M | $48.9M |
| Free cash flow | -$534.8M | -$399.8M | -$415.7M | -$310.9M | -$191.4M |
Shares outstanding 124.4M · Free float 94.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.